Optimization of contrast timing for breath-hold three-dimensional MR angiography.
The purpose of this study was to determine the influence of various factors (age, weight, breathing, saline flush) on the contrast kinetics of a test bolus injection for the purpose of calculating the scan delay for optimized contrast-enhanced three-dimensional MR angiography. Initially, the test bolus administration was optimized by evaluating the influence of breathing (breathing versus breath-hold) and the administration of a saline flush after the contrast injection (no flush versus flush) on the kinetics of a 4-ml Gd-DTPA test bolus injection in three healthy volunteers. Subsequently, in 33 patients referred for three-dimensional MR angiography of the renal arteries, test bolus kinetics were correlated to age, weight, and heart rate. In addition, the image quality of the three-dimensional MR angiograms was assessed on a four-point scale with regard to vessel visibility. The administration of a saline flush after the contrast injection significantly shortened the first appearance time (14 versus 16 seconds, P < .05), as well as the time to maximal signal intensity (SI) (6 versus 10 seconds, P < .05) and increased both maximum (67 versus 151 seconds, P < .05) and the SI slope (6.4 versus 20.5 seconds, P < .05). Breath-holding was shown to have no significant affect on the test bolus kinetics. No correlation was found between physiologic parameters and test bolus kinetics in the patient group. Image quality was graded as sufficient for diagnostic purposes in 32 of 33 patients. The contrast travel time from injection site to the vascular system under consideration cannot be predicted based on physiologic parameters. This time interval can be reliably and accurately determined by a test bolus injection of a small volume of contrast agent followed by a saline flush during normal breathing.
Hany
T F
TF
Department of Diagnostic Radiology, University Hospital Zürich, Switzerland.
McKinnon
G C
GC
Leung
D A
DA
Pfammatter
T
T
Debatin
J F
JF
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001011:Aorta / Q000033:anatomy & histology*; D003287:Contrast Media / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D018810:Magnetic Resonance Angiography / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004369:Pentetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011856:Radiographic Image Enhancement; D012077:Renal Artery / Q000033:anatomy & histology*; D012119:Respiration; D012680:Sensitivity and Specificity; D013997:Time Factors
D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D019786:Gadolinium DTPA